Section Arrow
Quote
ALLR.NASDAQ
- Allarity Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/18 16:31 EDT
After Hours
Last
 1.01
+0.0134 (+1.34%)
Bid
0.99
Ask
1.01
High 1.01 
Low 0.96 
Volume 556 
Regular Hours
Last
 0.9966
-0.0034 (-0.34%)
Day High 
1.03 
Prev. Close
1 
1-M High
1.1 
Volume 
211.55K 
Bid
0.99
Ask
1.01
Day Low
0.9611 
Open
0.99 
1-M Low
0.7947 
Market Cap 
15.08M 
Currency USD 
P/E 0 
%Yield -- 
10-SMA 1.02 
20-SMA 1 
50-SMA 0.97 
52-W High 7.38 
52-W Low 0.6138 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
648.26/--
Enterprise Value
16.16M
Balance Sheet
Book Value Per Share
1.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
After Hours 2.2001 -0.0799 -3.50%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
After Hours 14.17 +0.095 +0.67%
NCNANuCana plc0.0477+0.0009+1.92%-- 
After Hours 0.04725 -0.00045 -0.94%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
After Hours 5.86 +0.02 +0.34%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
After Hours 5.75 -0.17 -2.87%
Quotes are at least 15-min delayed：2025/07/18 16:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.